Argos Therapeutics Company Profile (NASDAQ:ARGS)

About Argos Therapeutics

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARGS
  • CUSIP:
Key Metrics:
  • Previous Close: $1.35
  • 50 Day Moving Average: $4.607
  • 200 Day Moving Average: $4.697
  • 52-Week Range: $1.20 - $13.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.05
  • P/E Growth: 0.000
  • Market Cap: $50.53M
  • Outstanding Shares: 41,246,000
  • Beta: 2.1
Profitability:
  • Net Margins: -6,452.34%
  • Return on Assets: -88.70%
Debt:
  • Debt-to-Equity Ratio: 1.81%
  • Current Ratio: 2.98%
  • Quick Ratio: 2.98%
Additional Links:
Companies Related to Argos Therapeutics:

Analyst Ratings

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (?)
Ratings Breakdown: 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $9.49 (674.34% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2017FBR & CoReiterated RatingHoldView Rating Details
2/22/2017Needham & Company LLCDowngradeBuy -> HoldView Rating Details
2/22/2017JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/22/2017Stifel NicolausDowngradeBuy -> Hold$1.40View Rating Details
6/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$11.00View Rating Details
4/19/2016Roth CapitalBoost Price TargetBuy$11.00 -> $18.00View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details
6/9/2015MLV & Co.Set Price TargetBuy$13.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Argos Therapeutics (NASDAQ:ARGS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/14/2016Q3 2016($0.35)($0.32)ViewN/AView Earnings Details
8/10/2016Q2($0.43)($0.48)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.57)ViewListenView Earnings Details
3/29/2016Q4($0.88)($0.84)ViewListenView Earnings Details
11/16/2015Q315($0.92)($0.97)$158.35 millionViewListenView Earnings Details
8/12/2015Q215($0.80)($0.95)ViewListenView Earnings Details
5/14/2015Q115($0.80)($0.89)ViewListenView Earnings Details
3/30/2015Q314($0.73)($0.83)ViewN/AView Earnings Details
11/13/2014($0.65)($0.77)ViewN/AView Earnings Details
8/13/2014Q214($0.60)($0.61)$1.27 million$1.26 millionViewN/AView Earnings Details
5/13/2014Q114($0.46)($1.05)$1.26 million$0.80 millionViewN/AView Earnings Details
3/27/2014($2.63)($36.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Argos Therapeutics (NASDAQ:ARGS)
Current Year EPS Consensus Estimate: $-1.590 EPS
Next Year EPS Consensus Estimate: $-1.170 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.70)($0.54)($0.62)
Q2 20162($0.58)($0.52)($0.55)
Q3 20162($0.33)($0.32)($0.33)
Q4 20162($0.34)($0.30)($0.32)
Q1 20171($0.31)($0.31)($0.31)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Argos Therapeutics (NASDAQ:ARGS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Argos Therapeutics (NASDAQ:ARGS)
Insider Ownership Percentage: 61.64%
Institutional Ownership Percentage: 15.25%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/7/2016International S PharmstandardMajor ShareholderBuy31,704$4.73$149,959.92View SEC Filing  
9/29/2016International S PharmstandardMajor ShareholderBuy43,618$4.56$198,898.08View SEC Filing  
9/20/2016International S PharmstandardMajor ShareholderBuy41,259$4.77$196,805.43View SEC Filing  
9/19/2016International S PharmstandardMajor ShareholderBuy5,580$4.76$26,560.80View SEC Filing  
9/16/2016International S PharmstandardMajor ShareholderBuy52,512$4.77$250,482.24View SEC Filing  
9/1/2016International S PharmstandardMajor ShareholderBuy16,977$4.78$81,150.06View SEC Filing  
8/24/2016International S PharmstandardMajor ShareholderBuy67,371$4.52$304,516.92View SEC Filing  
8/22/2016International S PharmstandardMajor ShareholderBuy75,474$4.24$320,009.76View SEC Filing  
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.00View SEC Filing  
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.00View SEC Filing  
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.00View SEC Filing  
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.00View SEC Filing  
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.00View SEC Filing  
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.00View SEC Filing  
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.00View SEC Filing  
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Argos Therapeutics (NASDAQ:ARGS)
DateHeadline
News IconTrading Scope: Checking on Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) - SKV News (NASDAQ:ARGS)
skvnews.com - February 25 at 1:51 AM
News IconStocks Movement Analysis: CEL-SCI Corporation (NYSEMKT:CVM), Argos Therapeutics, Inc. (NASDAQ:ARGS) - The Newburgh Press (NASDAQ:ARGS)
newburghpress.com - February 24 at 3:48 PM
News IconHot Stocks Report: Anthera Pharmaceuticals, Inc. (ANTH), Argos ... - Post Analyst (NASDAQ:ARGS)
www.postanalyst.com - February 24 at 3:48 PM
News IconShares Bending Lower in Session: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 24 at 3:48 PM
News IconWatching the Technicals on Shares of Argos Therapeutics Inc (ARGS) - The Standard (NASDAQ:ARGS)
6milestandard.com - February 24 at 12:36 PM
News IconArgos Therapeutics, Inc. (NASDAQ:ARGS) on Watch After Reaching Key Levels - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 23 at 3:37 PM
News IconMomentum Watch on Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) - Midway Monitor (NASDAQ:ARGS)
midwaymonitor.com - February 23 at 1:41 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics ... - Business Wire (press release) (NASDAQ:ARGS)
www.businesswire.com - February 23 at 1:41 AM
us.rd.yahoo.com logoArgos Therapeutics downgraded by FBR & Co. and JMP Securities (NASDAQ:ARGS)
us.rd.yahoo.com - February 22 at 8:40 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics, Inc. (NASDAQ:ARGS)
finance.yahoo.com - February 22 at 8:40 PM
benzinga.com logo18 Biggest Mid-Day Losers For Wednesday - Benzinga (NASDAQ:ARGS)
www.benzinga.com - February 22 at 3:38 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Dow Chemical, DuPont, Garmin, United Therapeutics - Nasdaq (NASDAQ:ARGS)
www.nasdaq.com - February 22 at 3:38 PM
News IconMarket Review: Focusing on This Stock: Argos Therapeutics Inc (ARGS) - Rives Journal (NASDAQ:ARGS)
rivesjournal.com - February 22 at 3:38 PM
smarteranalyst.com logoArgos Therapeutics Inc (ARGS): Run, Forrest, Run! - Smarter Analyst (NASDAQ:ARGS)
www.smarteranalyst.com - February 22 at 3:38 PM
bizjournals.com logoArgos stock sinks more than 65 percent following recommendation to stop trial (NASDAQ:ARGS)
www.bizjournals.com - February 22 at 3:38 PM
streetinsider.com logoPre-Open Stock Movers 02/22: (SRRA) (GRMN) (TOL) Higher; (ARGS) (SREV) (TXRH) Lower (more...) (NASDAQ:ARGS)
www.streetinsider.com - February 22 at 11:26 AM
finance.yahoo.com logo8:00 am Argos Therapeutics announces that the Independent Data Monitoring Committee for the Phase 3 ADAPT clinical trial of rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of metastatic renal cell carcinoma (NASDAQ:ARGS)
finance.yahoo.com - February 22 at 11:26 AM
finance.yahoo.com logoIndependent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review (NASDAQ:ARGS)
finance.yahoo.com - February 22 at 11:26 AM
biz.yahoo.com logoARGOS THERAPEUTICS INC Files SEC form 8-K, Other Events (NASDAQ:ARGS)
biz.yahoo.com - February 22 at 11:26 AM
marketwatch.com logoArgos Therapeutics cancer treatment study recommended to be discontinued for futility (NASDAQ:ARGS)
www.marketwatch.com - February 22 at 11:26 AM
finance.yahoo.com logoArgos says independent committee suggests stopping carcinoma study (NASDAQ:ARGS)
finance.yahoo.com - February 22 at 11:26 AM
thestreet.com logoArgos Plummets 72%, Leads Biotech Movers (NASDAQ:ARGS)
www.thestreet.com - February 22 at 11:26 AM
finance.yahoo.com logoArgos says independent committee predicts trial failure, shares slump (NASDAQ:ARGS)
finance.yahoo.com - February 22 at 11:26 AM
thestreet.com logoArgos Therapeutics Tanks on Committee Suggestion to Stop Carcinoma Drug Study (NASDAQ:ARGS)
www.thestreet.com - February 22 at 11:26 AM
News IconSell-side Consensus Sees Argos Therapeutics, Inc. (NASDAQ:ARGS) Going Where Near-Term? - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 21 at 8:48 AM
News IconArgos Therapeutics, Inc. (NASDAQ:ARGS) Price Target & Session Check - Rockville Register (NASDAQ:ARGS)
rockvilleregister.com - February 17 at 6:32 PM
News IconTrading Center: Following Shares of Argos Therapeutics Inc (ARGS) - Benton Bulletin (NASDAQ:ARGS)
bentonbulletin.com - February 17 at 6:32 PM
News IconChart Watch: Following Indicators on Shares of Argos Therapeutics Inc (ARGS) - The Standard (NASDAQ:ARGS)
6milestandard.com - February 16 at 8:31 AM
News IconNoteworthy Tuesday Option Activity: IMAX, HUBS, ARGS (NASDAQ:ARGS)
www.stockoptionschannel.com - February 15 at 2:16 AM
News IconArgos Therapeutics, Inc. (ARGS) expected to move 5% in response to its earnings report - Post Analyst (NASDAQ:ARGS)
postanalyst.com - February 13 at 9:06 PM
globenewswire.com logoArgos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium - GlobeNewswire (press release) (NASDAQ:ARGS)
globenewswire.com - February 13 at 9:06 PM
finance.yahoo.com logoArgos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium (NASDAQ:ARGS)
finance.yahoo.com - February 13 at 4:05 PM
News IconTrading Center: Following Shares of Argos Therapeutics Inc (ARGS) - Providence Standard (NASDAQ:ARGS)
providencestandard.com - February 8 at 3:53 PM
News IconA Favorite Among Institutions: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Midway Monitor (NASDAQ:ARGS)
midwaymonitor.com - February 8 at 3:53 PM
News IconStock Churning Higher Mid-Day Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 6 at 3:37 PM
News IconUnusual Volume Sighted in Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 6 at 3:37 PM
seekingalpha.com logoArgos Therapeutics: Interview With CEO Jeff Abbey And VP Communications John Menditto - Seeking Alpha (NASDAQ:ARGS)
seekingalpha.com - February 6 at 3:37 PM
globenewswire.com logoArgos Therapeutics to Participate in BIO CEO and Investor Conference - GlobeNewswire (press release) (NASDAQ:ARGS)
globenewswire.com - February 6 at 3:37 PM
nasdaq.com logoIs the Options Market Predicting a Spike in Argos Therapeutics (ARGS) Stock? - Nasdaq (NASDAQ:ARGS)
www.nasdaq.com - February 6 at 3:37 PM
finance.yahoo.com logoArgos Therapeutics to Participate in BIO CEO and Investor Conference (NASDAQ:ARGS)
finance.yahoo.com - February 6 at 3:37 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Argos Therapeutics (ARGS) Stock? (NASDAQ:ARGS)
finance.yahoo.com - February 6 at 3:37 PM
investornewswire.com logoSentiments And Ratings Alert: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Investor Newswire (NASDAQ:ARGS)
www.investornewswire.com - February 5 at 3:37 PM
News IconNotable Thursday Option Activity: ARGS, CGI, MNKD (NASDAQ:ARGS)
www.stockoptionschannel.com - February 2 at 3:40 PM
News IconArgos Therapeutics Inc (ARGS) Stock Faces Higher Risks Forward After Forming Bearish Double Bottom (NASDAQ:ARGS)
randolphguide.com - February 2 at 3:40 PM
News IconArgos Therapeutics Inc (ARGS) Stock Faces Higher Risks Forward After Forming Bearish Double Bottom (NASDAQ:ARGS)
randolphguide.com - February 2 at 3:40 PM
News IconStock Dragging Lower Heading Into The Open: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 1 at 3:45 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Argos Therapeutics, Inc. (NASDAQ:ARGS)? - Wall Street Beacon (NASDAQ:ARGS)
wsbeacon.com - January 31 at 3:50 PM
News IconStock in Focus: Argos Therapeutics, Inc. (NASDAQ:ARGS) - The Tribune (NASDAQ:ARGS)
lakecitytribune.com - January 31 at 2:44 AM
News IconHigh Volatility Moving the Needle For Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) - Wall Street Beacon (NASDAQ:ARGS)
wsbeacon.com - January 31 at 2:44 AM
News IconStock Watch for Argos Therapeutics, Inc. (NASDAQ:ARGS) - Gilbert Daily (NASDAQ:ARGS)
gilbertdaily.com - January 29 at 8:33 PM

Social

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

Where is Argos Therapeutics' stock going? Where will Argos Therapeutics' stock price be in 2017?

7 equities research analysts have issued 12-month price objectives for Argos Therapeutics' shares. Their predictions range from $1.40 to $18.00. On average, they expect Argos Therapeutics' share price to reach $9.49 in the next twelve months.

When will Argos Therapeutics announce their earnings?

Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

What are analysts saying about Argos Therapeutics stock?

Here are some recent quotes from research analysts about Argos Therapeutics stock:

  • FBR & Co analysts commented, "On the morning of February 22, Argos Therapeutics announced that the Independent Data Monitoring Committee (IDMC) recommended that the company’s pivotal Phase III ADAPT clinical trial of rocapuldencel-T (AGS-003) in combination with sunitinib (standard therapy) for the treatment of metastatic renal cell carcinoma (mRCC) be discontinued for futility based on its planned interim data analysis. The IDMC came to a conclusion that the study was unlikely to demonstrate a statistically significant improvement in overall survival (OS) in the combination treatment arm of rocapuldencel-T and sunitinib. The company is in the process of analyzing preliminary data from the trial, and its next steps involve discussing the data with the FDA." (2/23/2017)

  • Needham & Company LLC analysts commented, "Argos announced that the pivotal Phase III ADAPT trial of rocapuldencel-T (AGS-003) in renal cell carcinoma (RCC) reached futility at a pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has recommended discontinuation of the trial. Argos plans to leave the trial open pending further data review and FDA discussion, however, we view the likelihood of approval in RCC, our main valuation driver, as too uncertain. We are downgrading shares to Neutral." (2/22/2017)
  • According to Zacks Investment Research, "Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. " (2/7/2017)

Who owns Argos Therapeutics stock?

Argos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (0.43%), Wall Street Associates (0.20%) and Keybank National Association OH (0.06%). Company insiders that own Argos Therapeutics stock include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.

Who sold Argos Therapeutics stock? Who is selling Argos Therapeutics stock?

Argos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates.

Who bought Argos Therapeutics stock? Who is buying Argos Therapeutics stock?

Argos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have bought Argos Therapeutics stock in the last two years include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.

How do I buy Argos Therapeutics stock?

Shares of Argos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Argos Therapeutics stock cost?

One share of Argos Therapeutics stock can currently be purchased for approximately $1.23.

Argos Therapeutics (NASDAQ:ARGS) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Earnings History Chart

Earnings by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Dividend History Chart

Dividend Payments by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Last Updated on 2/25/2017 by MarketBeat.com Staff